ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Prime Medicine, Inc. (PRME) stock declined over -6.40%, trading at $1.17 on NASDAQ, down from the previous close of $1.25. The stock opened at $1.23, fluctuating between $1.13 and $1.29 in the recent session.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Employees | 214 |
Beta | 1.85 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep